Short answer
UNITED THERAPEUTICS Corp (UTHR) filed an 8-K current report with the SEC on October 14, 2026 reporting Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). Liquidia settlement provides UTHR $330.4M, including $185M for past Yutrepia PH-ILD sales and $145.4M through April 2027.
UNITED THERAPEUTICS Corp 8-K event analysis
AI summary of each reported item and its exhibits
Item 8.01 · Other Events
- Liquidia settlement provides UTHR $330.4M, including $185M for past Yutrepia PH-ILD sales and $145.4M through April 2027
- Yutrepia must remove its PH-ILD indication, restricting Liquidia’s marketing, sales, payer access and related clinical-trial activity
- Agreement protects UTHR’s PH-ILD franchise through the ’327 patent, expiring February 3, 2042
- UTHR pays Liquidia $10.0M to settle RareGen/Sandoz litigation, eliminating exposure to the vacated $61.6M damages award
- Settlement remains subject to FDA label action, third-party consents, payments and litigation dismissals
Item EX-99.1 · Exhibit EX-99.1
- Liquidia owes UTC $330.4M total: $185M immediate damages plus $145.4M for future PH-ILD sales
- UTC pays Liquidia $10M to resolve one proceeding, making net stated cash consideration to UTC $320.4M
- Yutrepia PH-ILD sales, marketing, promotion and related ASCENT trial activity must cease after FDA label removal
- Liquidia must secure an irrevocable letter of credit covering its $330.4M obligations within 10 Business Days
- Settlement dismisses contested proceedings with prejudice, while preserving certain claims involving Robert Roscigno and future conduct
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other UNITED THERAPEUTICS Corp 8-K filings
Get the next UTHR 8-K as it lands
Follow UTHR for push alerts, or ask the research agent what this filing means.